|High Income Countries:||Middle-Income Countries:||Low-Income Countries:|
|High Income Countries|
In October 2000, Chiron and Roche resolved all pending litigation between them in the United States, Italy, Japan, the Netherlands, Belgium, Germany and Australia regarding HCV and HIV nucleic acid technology. Among the settlement provisions, Chiron granted Roche licenses to manufacture and sell HCV and HIV nucleic acid clinical diagnostic tests. Chiron also agreed to license Roche for a limited time period to sell HCV and HIV nucleic acid tests for blood screening.
In December 2000, Roche initiated two nullity actions against Chiron's German national patents (the '104, '524 and '527 patents), and the European '931 patent in the German Federal Patent Court ("Bundespatentgericht"). In January 2001, the Bundespatentgericht divided the German patent suit into three individual actions.
Bio-Technology General Corp. (BTG), Iselin, New Jersey, announced that the Israeli Registrar of Patents has ruled that Bio-Technology General (Israel), is entitled to a compulsory license to Biogen's Israeli patent No. 59007 which relates to genetically engineered hepatitis B vaccine. The Registrar's decision follows proceedings which began in January 1992 when BTG filed its application for a compulsory license.
|Middle Income Countries|
Half a year earlier, US Secretary of Commerce Donald Evans, had written the Korean Ministers of Health and Trade, threatening a "serious trade dispute" over drug pricing. The request for a compulsory license was quickly denied.
|Low Income Countries|
|Return to: CPTech Home -> Main IP Page -> IP and Healthcare -> Compulsory Licensing Home|